Short Interest in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Drops By 57.7%

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a large decrease in short interest in the month of January. As of January 30th, there was short interest totaling 1,303 shares, a decrease of 57.7% from the January 15th total of 3,079 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily volume of 8,921 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 8,921 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.1% of the company’s shares are sold short.

Global X Genomics & Biotechnology ETF Trading Down 1.8%

GNOM traded down $0.84 on Thursday, hitting $45.32. The company had a trading volume of 5,886 shares, compared to its average volume of 9,582. The firm has a market cap of $49.40 million, a P/E ratio of -19.37 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a 1 year low of $27.20 and a 1 year high of $51.42. The company’s fifty day moving average price is $47.28 and its 200 day moving average price is $42.55.

Global X Genomics & Biotechnology ETF Dividend Announcement

The business also recently declared a dividend, which was paid on Wednesday, January 7th. Shareholders of record on Tuesday, December 30th were given a dividend of $0.5912 per share. The ex-dividend date was Tuesday, December 30th. This represents a dividend yield of 259.0%. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is currently -26.50%.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GNOM. Jane Street Group LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 7.7% during the first quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock worth $1,143,000 after purchasing an additional 10,308 shares in the last quarter. Insight Advisors LLC PA grew its position in shares of Global X Genomics & Biotechnology ETF by 47.9% during the second quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after buying an additional 19,319 shares in the last quarter. Oppenheimer Asset Management Inc. grew its position in shares of Global X Genomics & Biotechnology ETF by 8.1% during the second quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after buying an additional 6,708 shares in the last quarter. Atria Investments Inc increased its holdings in Global X Genomics & Biotechnology ETF by 12.6% in the second quarter. Atria Investments Inc now owns 18,520 shares of the company’s stock valued at $156,000 after buying an additional 2,073 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV grew its stake in Global X Genomics & Biotechnology ETF by 86.7% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 22,301 shares of the company’s stock worth $188,000 after buying an additional 10,358 shares during the last quarter. 56.95% of the stock is currently owned by institutional investors and hedge funds.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.